Skye to Showcase Nimacimab Phase 2a Add-On Data with Semaglutide on April 16
Skye Bioscience will present on April 16 at the GLP-1-Based Therapeutics Summit in Boston its peripheral CB1 antagonist nimacimab, detailing its Phase 2a additive effects when combined with semaglutide. Nimacimab, a peripherally-restricted monoclonal antibody, aims to drive incremental weight loss and prevent weight regain without CNS side effects.
1. Upcoming GLP-1 Therapeutics Summit Presentation
Skye Bioscience will deliver a presentation titled “Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm” at the GLP-1-Based Therapeutics Summit in Boston on April 16 at 1:30 pm, presented by President & CEO Punit Dhillon.
2. Nimacimab Development and Trial Data
Nimacimab is a peripherally-restricted monoclonal antibody targeting the CB1 receptor designed to avoid CNS penetration and neuropsychiatric side effects seen with small-molecule antagonists. In the Phase 2a CBeyond trial, nimacimab demonstrated additive weight loss effects when combined with semaglutide and is being developed as an orthogonal add-on therapy for patients plateaued on GLP-1 treatment.